Abstract
Altered expressions of receptor for advanced glycation end-products (RAGE) and its ligand (S100A9) are observed in many cancers and play a key role in inflammation-associated cancer. In our previous study, by two-dimensional gel electrophoresis followed by mass spectrometry, the expression of S100A9 protein was found to increase in squamous cervical cancer compared with adjacent normal cervical tissues. Therefore, in the present study we observed the expressions of S100A9 and RAGE in 30 chronic cervicitis, 50 cervical intraepithelial neoplasia (CIN), and 40 squamous cervical cancer (SCC) using immunohistochemical analysis and analyzed the differential expression and possible role of S100A9 and RAGE in cancer development. Immunohistochemical findings were as follows: the expressions of S100A9 and RAGE were demonstrated in chronic cervicitis, CIN, and SCC. Moreover, their expressions were gradually increasing as the tumor progressed. In SCC, the staining scores of S100A9 and RAGE were significantly higher in well-differentiated tumors compared to moderately and poorly differentiated tumors. The expression of S100A9 in epithelial cells exhibited a positive correlation to RAGE expression in chronic cervicitis, CIN, and SCC. There were no significant difference of S100A9 immunoreactivity in stromal cells among chronic cervicitis, CIN, and SCC. Moreover, there was no correlation between S100A9 immunoreactivity in stromal cells of SCC and clinicopathological parameters. Finally, double immunohistochemistry illustrated that RAGE and S100A9 co-express in SCC. In conclusion, RAGE binds its ligand (S100A9), which plays an important role in the development of SCC. In addition, the expressions of S100A9 and RAGE in SCC tumor cells were closely associated with histological differentiation.
Similar content being viewed by others
Abbreviations
- RAGE:
-
Receptor for advanced glycation end products
- CIN:
-
Cervical intraepithelial neoplasia
- SCC:
-
Squamous cervical cancer
References
Petignat, P., & Roy, M. (2007). Diagnosis and management of cervical cancer. BMJ, 335, 765–768.
Tiltman, A. J. (2005). The pathology of cervical tumours. Best Practice & Research Clinical Obstetrics & Gynaecology, 19, 485–500.
Logsdon, C. D., Fuentes, M. K., Huang, E. H., et al. (2007). RAGE and RAGE ligands in cancer. Current Molecular Medicine, 7, 777–789.
Bucciarelli, L. G., Wendt, T., Rong, L., et al. (2002). RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeostasis and chronic disease. Cellular and Molecular Life Sciences, 59, 1117–1128.
Douqan, M., & Dranoff, G. (2008). Inciting inflammation: The RAGE about tumor promotion. Journal of Experimental Medicine, 205, 267–270.
Hiwatashi, K., Ueno, S., Abeyama, K., et al. (2008). A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC. Annals of Surgical Oncology, 15, 923–933.
Hessian, P. A., Edgeworth, J., & Hogg, N. (1993). MRP-8 and MRP-14, two abundant Ca2+ binding proteins of neutrophils and monocytes. Journal of Leukocyte Biology, 53, 197–204.
Gebhardt, C., Németh, J., Angel, P., et al. (2006). S100A8 and S100A9 in inflammation and cancer. Biochemical Pharmacology, 72, 1622–1631.
Chao, A., Wang, T. H., Lee, Y. S., et al. (2006). Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. International Journal of Cancer, 119, 91–98.
Zhu, X., Lv, J., Yu, L., et al. (2009). Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecologic Oncology, 112, 248–256.
Turovskaya, O., Foell, D., Sinha, P., et al. (2008). RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis, 29, 2035–2043.
Hermani, A., Hess, J., De Servi, B., et al. (2005). Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clinical Cancer Research, 11, 5146–5152.
Sasahira, T., Kirita, T., Bhawal, U. K., et al. (2007). Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology, 51, 166–172.
Arai, K., Teratani, T., Kuruto-Niwa, R., et al. (2004). S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. European Journal of Cancer, 40, 1179–1187.
Moss, S. F., & Blaser, M. J. (2005). Mechanisms of disease: Inflammation and the origins of cancer. Nature Clinical Practice Oncology, 2, 90–97.
Huang, E. H., Park, J. C., Appelman, H., et al. (2006). Induction of inflammatory bowel disease accelerates adenoma formation in min ± mice. Surgery, 139, 782–788.
Bhawal, U. K., Ozaki, Y., Nishimura, M., et al. (2005). Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology, 69, 246–255.
Sasahira, T., Kirita, T., Bhawal, U. K., et al. (2007). The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Archiv, 450, 287–295.
Landesberg, R., Woo, V., Huang, L., et al. (2008). The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics, 105, 617–624.
Kong, J. P., Ding, F., Zhou, C. N., et al. (2004). Loss of myeloid-related proteins 8 and myeloid-related proteins 14 expression in human esophageal squamous cell carcinoma correlates with poor differentiation. World Journal of Gastroenterology, 10, 1093–1097.
Sewell, D. A., Yuan, C. X., & Robertson, E. (2007). Proteomic signatures in laryngeal squamous cell carcinoma. Journal of Oto-Rhino-Laryngology and Its Related Specialties, 69, 77–84.
He, Q. Y., Chen, J., Kung, H. F., et al. (2004). Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics, 4, 271–278.
Arai, K., Teratani, T., Nozawa, R., et al. (2001). Immunohistochemical investigation of S100A9 expression in pulmonary adenocarcinoma: S100A9 expression is associated with tumor differentiation. Oncology Reports, 8, 591–596.
Ghavami, S., Rashedi, I., Dattilo, B. M., et al. (2008). S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. Journal of Leukocyte Biology, 83, 1484–1492.
Gebhardt, C., Riehl, A., Durchdewald, M., et al. (2008). RAGE signaling sustains inflammation and promotes tumor development. Journal of Experimental Medicine, 205, 275–285.
Garg, A. K., Jhingran, A., Klopp, A. H., et al. (2010). Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. International Journal of Radiation Oncology Biology Physics, 78, 1331–1336.
Sheikh, A. A., Vimalachandran, D., Thompson, C. C., et al. (2007). The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics, 7, 1929–1940.
Acknowledgments
This study was supported by the Special Foundation for Outstanding Young Scientists of Zhejiang Province, China (Grant No. 2009QN023), and a grant of science and technology project in Wenzhou (No. Y20080153).
Conflict of interest
All the authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhu, X., Jin, L., Zou, S. et al. Immunohistochemical Expression of RAGE and Its Ligand (S100A9) in Cervical Lesions. Cell Biochem Biophys 66, 843–850 (2013). https://doi.org/10.1007/s12013-013-9515-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12013-013-9515-x